医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

多中心食管鳞状细胞癌提高三维放疗剂量临床疗效分析——3JECROG R-03

Clinical efficacy of dose escalation in 3-dimensional radiotherapy for patients with esophageal squamous cell carcinoma-multicenter retrospective analysis (3JECROG R-03)

摘要目的:比较食管鳞状细胞癌行根治性放疗不同放疗剂量对生存的影响,并探讨预后影响因素。方法:回顾性分析2002-2016年中国10所医疗中心2 344例接受根治性放化疗/放疗的食管鳞状细胞癌患者临床资料,经1∶2倾向性评分配比(PSM),根据放疗剂量分为低剂量组(EQD 2Gy<60 Gy)303例,高剂量组(EQD 2Gy≥60 Gy)606例。 Kaplan- Meier法生存分析, Cox模型多因素预后分析。 结果:中位随访时间为59.6个月。经PSM配比后,低剂量组和高剂量组的1、3、5年总生存率分别为66.5%、34.7%、27.2%和72.9%、41.7%、34.7%( P=0.018),无进展生存率分别为52.2%、27.2%、23.1%和58.3%、38.1%、33.9%( P=0.001)。单因素结果显示颈段/胸上段食管癌、临床分期早、无区域淋巴结转移、病变长度短、采用IMRT技术、接受同步化疗、EQD 2Gy≥60 Gy为总生存获益因素(均 P<0.05)。多因素结果显示肿瘤部位、有无区域淋巴结转移、是否接受同步化疗以及EQD 2Gy是影响总生存的重要因素(均 P<0.05)。 结论:局部晚期食管鳞状细胞癌患者应用三维适形或调强放疗EQD 2Gy≥60 Gy时生存获益。

更多

abstractsObjective:To evaluate the effect of definitive radiotherapy with different doses on overall survival (OS) and identify the prognostic factors of patients with non-metastatic esophageal squamous cell carcinoma (ESCC).Methods:Clinical data of 2 344 ESCC patients treated with definitive radiotherapy (RT) alone or chemoradiotherapy from 2002 to 2016 in 10 hospitals were collected and analyzed retrospectively. After the propensity score matching (PSM)(1 to 2 ratio), all patients were divided into the low-dose group (equivalent dose in 2 Gy fractions, EQD 2Gy<60 Gy; n=303) and high-dose group (EQD 2Gy≥60 Gy; n=606) based on the dose of radiation. Survival analysis was conducted by Kaplan- Meier method. Multivariate prognostic analysis was performed by Cox′s regression model. Results:The median follow-up time was 59.6 months. After the PSM, the 1-, 3- and 5-year overall survival (OS) rate was 66.5%, 34.7%, 27.2% in the low-dose group, 72.9%, 41.7% and 34.7% in the high-dose group, respectively ( P=0.018). The 1-, 3-and 5-year progression-free survival rate was 52.2%, 27.2%, 23.1% in the low-dose group, 58.3%, 38.1% and 33.9% in the high-dose group, respectively ( P=0.001). The outcomes of univariate analysis indicated that cervical/upper esophagus location, early (stage Ⅱ) AJCC clinical stage, node negative status, tumor length ≤5 cm, receiving intensity-modulated radiation therapy (IMRT), receiving concurrent chemotherapy and EQD 2Gy≥60 Gy were closely associated with better OS (all P<0.05). Multivariable analysis demonstrated that tumor location, regional lymph node metastasis, concurrent chemotherapy and EQD 2Gy were the independent prognostic factors for OS (all P<0.05). Conclusion:Three-dimensional conformal or IMRT with EQD 2Gy≥60 Gy yields favorable survival outcomes for patients with locally advanced ESCC.

More
广告
作者 赵晶晶 [1] 章文成 [1] 张华雷 [1] 韩炜明 [2] 王鑫 [2] 李晨 [2] 陈俊强 [3] 王晓敏 [4] 赵一电 [4] 乔学英 [5] 周志国 [5] 韩春 [5] 祝淑钗 [5] 沈文斌 [5] 王澜 [5] 葛小林 [6] 孙新臣 [6] 张开贤 [7] 胡苗苗 [7] 李苓 [7] 郝崇礼 [7] 李高峰 [8] 徐勇刚 [8] 王雅棣 [9] 路娜 [9] 刘妙玲 [10] 郄帅 [10] 肖泽芬 [2] 庞青松 [1] 王平 [1] 学术成果认领
栏目名称
DOI 10.3760/cma.j.cn113030-20191014-00417
发布时间 2020-11-15(万方平台首次上网日期,不代表论文的发表时间)
  • 浏览247
  • 下载197
中华放射肿瘤学杂志

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

扩展文献

法律状态公告日 法律状态 法律状态信息

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷